NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.86 +0.84 (+1.08%) GOLD FUTURES
2,393.40 +33.50 (+1.42%) DOW
39,908.00 +349.89 (+0.88%) Bitcoin GBP
52,087.77 +3,536.12 (+7.28%)
Vanda Pharmaceuticals Inc. (0LKB.L)
| Previous close | 5.09 |
| Open | 5.29 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 5.18 - 5.36 |
| 52-week range | 3.30 - 6.88 |
| Volume | |
| Avg. volume | 3,266 |
| Market cap | 2.751M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | 0.16 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results from its second Phase III study of tradipitant in motion sickness, confirming the previously reported results of two efficacy studies demonstrating that tradipitant is effective in the prevention of vomiting associated with motion sickness. This Phase III study was conducted in real-world conditions on boats in the coastal waters of the United States (U.S.).
- PR Newswire
Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2024.
- PR Newswire
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC ("Future Pak") to acquire the Company. The revised proposal consists of a $7.25 to $7.75 per share in cash plus certain Contingent Value Rights ("CVRs"). The amended proposal follows Vanda's review and rejection of a prior unsolicited proposal from Future Pak to acquire the Company for $7.25-$7.75 per share.
